EUVIMEDEUVIMED entdecken
Crossref

ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma

Cailu Song, Wenjian Liu, Xiaofang Xie, Cheng Peng, Lewei Zhu, Lingrui Liu, Yutian Zou, Xiaoming Xie, Hailin Tang, Jia Zhu, Chengcheng Liu, Hua Wang

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Cailu Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell, Programmed Cell Death 1 Receptor, Repressor Proteins, Drug Resistance, Neoplasm. Die Arbeit nennt 75 Literaturangaben. Gefördert von: Medical Science and Technology Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province, Chengdu University of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NK/T-cell lymphoma (NKTL) is a highly aggressive non-Hodgkin's lymphoma characterized by extranodal involvement. Programmed cell death protein 1 (PD-1) monoclonal antibody (anti-PD1) treatment is ineffective in some patients, leading to recurrence or metastasis. The resistance to anti-PD1 treatment remains a major challenge in clinics. To identify the core molecules responsible for anti-PD1 treatment resistance and explore the possible molecular mechanisms behind it, simulating the human immune microenvironment during PD-1 treatment is essential. In this study, human peripheral blood mononuclear cells (PBMCs) were transplanted into immunodeficient mice to reconstitute human immunity in mice. The results showed that after immune reconstitution, human immune cells, especially T cells, remain at a high level (≥90%) for at least 4 weeks, indicating that human PBMCs were successfully reconstituted in immunodeficient mice. Two weeks after PBMCs implantation, human NKTL cells (SNK1, KHYG1 and YT) were subcutaneously inoculated into the right lower abdomen of mice. Then, high-dose anti-PD1 treatment was initiated (about 50 mm3, Sintilimab, twice a week, 10 mg/kg each time). The tumor from the mice was removed (≤than 1500 mm3) to prepare a single-cell suspension and re-implanted into the mice. The above process was repeated 5 times (280 days in total). The tumor growth inhibition‌ (TGI) values of NKTL cells before and after induction (71.89% and 1.08% for KHYG1 cells, 54.37% and 3.79% for SNK1 cells, 51.17% and 6.34% for YT cells, respectively) confirmed the successful construction of anti-hPD1-induced resistance NKTL cells (SNK1-Re, KHYG1-Re and YT-Re). Subsequently, we performed transcriptomic, proteomic, and metabolomic analyses on the above resistant and sensitive cell lines. Through multiple functional experiments and clinical sample verification, we confirmed that the transcriptional repressor Zinc finger BED-type containing 6 (ZBED6) was a key biomarker for anti-PD1 treatment resistance in NKTL. Downregulated ZBED6 creates a thymidine-deficient environment by E2F transcription factor 1 (E2F1)-ribonucleoside-diphosphate reductase subunit M2 (RRM2)/dihydropyrimidine dehydrogenase (DPYD), in which drug-resistant tumor cells scavenge thymidine (TdR) from the tumor microenvironment via solute carrier family 29 member 1 (SLC29A1) to increase nucleotide synthesis, thereby establishing an immunosuppressive niche, resulting in the ineffectiveness of anti-PD1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Extranodal NK-T-CellProgrammed Cell Death 1 ReceptorRepressor ProteinsDrug Resistance, NeoplasmNucleotidesImmune Checkpoint InhibitorsAnimalsHumansMiceMetabolic ReprogrammingCell Line, TumorTumor MicroenvironmentXenograft Model Antitumor AssaysLeukocytes, MononuclearGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

NKTLPD-1 monoclonal antibodyPyrimidine synthesisTreatment sensitivityZBED6

Substanzen

Programmed Cell Death 1 ReceptorRepressor ProteinsNucleotidesPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Electronic address: songcl@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Electronic address: liuwj@sysucc.org.cn.
  • Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine,…
  • The First People's Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, Guangdong, China. Electroni…
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Electronic address: liulingr@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Electronic address: zouyt@sysucc.org.cn.

Förderung

  • Medical Science and Technology Foundation of Guangdong Province
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Chengdu University of Traditional Chinese Medicine

Zitieren

APA

Song, C., Liu, W., Xie, X., Peng, C., Zhu, L., Liu, L., Zou, Y., Xie, X., Tang, H., Zhu, J., Liu, C., & Wang, H. (2026). ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101466

Vancouver

Song C, Liu W, Xie X, Peng C, Zhu L, Liu L, et al. ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101466

BibTeX
@article{Song2026,
  author = {Song, Cailu and Liu, Wenjian and Xie, Xiaofang and Peng, Cheng and Zhu, Lewei and Liu, Lingrui and Zou, Yutian and Xie, Xiaoming and Tang, Hailin and Zhu, Jia and Liu, Chengcheng and Wang, Hua},
  title = {ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101466}
}
Kostenlos starten →